Preanalysis plans (PAPs) have become an important tool for limiting false discoveries in field experiments. We evaluate the properties of an alternate approach which splits the data into two samples:
b, d, the corresponding Osteoarthritis Research Society International (OARSI) scores from normal, sham, veh (vehicle)-treated, and BNTA-treated rats at 4 w and 8 w (n = 8 for each group; nonpar
Tolerogenic dendritic cells (tolDCs) are a promising treatment modality for diseases caused by a breach in immune tolerance, such as rheumatoid arthritis. Current medication for these diseases is dire
*Adapted from: Bendele, A., et al., Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis. Pharm Res, 1998. 15(10): p. 1557–61.
